{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:55:40Z","timestamp":1777658140524,"version":"3.51.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli studi \"Magna Graecia\" di Catanzaro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The use of immune-modifying biological agents has markedly changed the clinical course and the management of inflammatory bowel diseases (IBDs). Active post-marketing surveillance programs are essential for the early recognition of both expected and unexpected adverse events (AEs), providing a powerful tool for better defining the safety profiles of biologics in a real-world setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients diagnosed with IBDs and treated with biologic drugs at two gastroenterology units in Calabria, Italy, were monitored during the period from 2023 to 2024. AEs and drug switches or swaps were recorded. The primary objective was to assess the safety profile of biological therapies in real-world practice, as measured by the occurrence of AEs. Secondary objectives focused on assessing treatment effectiveness by monitoring rates of therapeutic ineffectiveness and rigorously analyzing necessary modifications to therapy (swaps\/switches) in response to treatment failure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 214 patients were enrolled, including 85 with Crohn\u2019s disease (CD) and 120 with ulcerative colitis (UC). Among biologics, vedolizumab (VDZ) was the most prescribed drug (50.3%), followed by ustekinumab (UST, 33.6%). Among biosimilars, infliximab (IFX) was the most administered (70%), followed by adalimumab (ADA) (63.3%). 96 patients experienced AEs, though no serious adverse events (SAEs) were reported. The highest number of AEs was reported with VDZ (<jats:italic>n<\/jats:italic>\u2009=\u200931; 32.3%), followed by IFX (<jats:italic>n<\/jats:italic>\u2009=\u200922, 23.0%), ADA and UST (<jats:italic>n<\/jats:italic>\u2009=\u200917, 17.7%), and golimumab (GOL) (<jats:italic>n<\/jats:italic>\u2009=\u20097; 7.3%). The biological drugs associated with the fewest AEs were upadacitinib (UPA) and tofacitinib (TFC) (<jats:italic>n<\/jats:italic>\u2009=\u20091; 1.0%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This study confirms the importance of pharmacovigilance in monitoring the safety of biologics in IBDs. The results offer useful insights into the actual use of monoclonals in gastroenterology and support more targeted prescribing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical trial number<\/jats:title>\n            <jats:p>Not applicable.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s43440-025-00774-x","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T06:54:25Z","timestamp":1755586465000},"page":"1415-1427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Real\u2011world safety and efficacy of biological agents in inflammatory bowel disease: a one-year post-marketing pharmacovigilance observational study in the Calabria region"],"prefix":"10.1007","volume":"77","author":[{"given":"Antonio","family":"Fabiano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"De Sarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Frajia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4766-9710","authenticated-orcid":false,"given":"Francesca","family":"Bosco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Guarnieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Ruga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Rodin\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ladislava","family":"Sebkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidoro","family":"Buoncompagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Costantino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianmarco","family":"Marcian\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Rania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"Citraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashour","family":"Michael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovambattista","family":"De Sarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"774_CR1","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fmicb.2016.00455","volume":"7","author":"A Mosca","year":"2016","unstructured":"Mosca A, Leclerc M, Hugot JP. Gut microbiota diversity and human diseases: should we reintroduce key predators in our ecosystem? Front Microbiol. 2016;7:455.","journal-title":"Front Microbiol"},{"key":"774_CR2","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.pop.2023.03.009","volume":"50","author":"LP Bruner","year":"2023","unstructured":"Bruner LP, White AM, Proksell S. Inflammatory bowel disease. Prim Care. 2023;50:411\u201327.","journal-title":"Prim Care"},{"key":"774_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cgh.2019.07.005","volume":"18","author":"C Le Berre","year":"2020","unstructured":"Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative colitis and crohn\u2019s disease have similar burden and goals for treatment. Clin Gastroenterol Hepatol. 2020;18:14\u201323.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"774_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3748\/wjg.v20.i1.133","volume":"20","author":"DG Lu","year":"2014","unstructured":"Lu DG, Ji XQ, Liu X, Li HJ, Zhang CQ. Pulmonary manifestations of crohn\u2019s disease. World J Gastroenterol. 2014;20:133\u201341.","journal-title":"World J Gastroenterol"},{"key":"774_CR5","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","volume":"15","author":"M Zhao","year":"2021","unstructured":"Zhao M, Gonczi L, Lakatos PL, Burisch J. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis. 2021;15:1573\u201387.","journal-title":"J Crohns Colitis"},{"key":"774_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.0105-2896.2005.00293.x","volume":"206","author":"GM Cobrin","year":"2005","unstructured":"Cobrin GM, Abreu MT. Defects in mucosal immunity leading to crohn\u2019s disease. Immunol Rev. 2005;206:277\u201395.","journal-title":"Immunol Rev"},{"key":"774_CR7","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1586\/egh.11.107","volume":"6","author":"A Geremia","year":"2012","unstructured":"Geremia A, Jewell DP. The IL-23\/IL-17 pathway in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2012;6:223\u201337.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"774_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","volume":"20","author":"YZ Zhang","year":"2014","unstructured":"Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20:91\u20139.","journal-title":"World J Gastroenterol"},{"key":"774_CR9","doi-asserted-by":"crossref","unstructured":"Imbrizi M, Magro F, Coy CSR. Pharmacological therapy in inflammatory bowel diseases: A narrative review of the past 90 years. Pharmaceuticals (Basel). 2023;16.","DOI":"10.3390\/ph16091272"},{"key":"774_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s11605-020-04832-y","volume":"25","author":"SC Lowe","year":"2021","unstructured":"Lowe SC, Sauk JS, Limketkai BN, Kwaan MR. Declining rates of surgery for inflammatory bowel disease in the era of biologic therapy. J Gastrointest Surg. 2021;25:211\u20139.","journal-title":"J Gastrointest Surg"},{"key":"774_CR11","doi-asserted-by":"crossref","unstructured":"Laredo V, Gargallo-Puyuelo CJ, Gomollon F. How to choose the biologic therapy in a Bio-naive patient with inflammatory bowel disease. J Clin Med. 2022;11.","DOI":"10.3390\/jcm11030829"},{"key":"774_CR12","doi-asserted-by":"crossref","unstructured":"Barbieri MA, Viola A, Cicala G, Spina E, Fries W. Effectiveness and safety profiles of biological therapies in inflammatory bowel disease: real life data from an active pharmacovigilance project. Biomedicines. 2022;10.","DOI":"10.3390\/biomedicines10123280"},{"key":"774_CR13","doi-asserted-by":"crossref","unstructured":"De Sarro C, Bosco F, Gagliardi A, Guarnieri L, Ruga S, Fabiano A et al. Prescribing pattern and safety profile of biological agents for psoriasis in Real-World practice: A Four-Year Calabrian pharmacovigilance analysis. Pharmaceutics. 2024;16.","DOI":"10.3390\/pharmaceutics16101329"},{"key":"774_CR14","unstructured":"ICH Harmonised Guideline: Integrated Addendum to ICH E6(R1.): Guideline for Good Clinical Practice E6(R2). International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). 2016."},{"key":"774_CR15","doi-asserted-by":"crossref","unstructured":"Tallarico M, Palleria C, Ruffolo L, Spagnuolo R, Naturale MD, De Francesco AE et al. Biologics for inflammatory bowel disease in clinical practice: A Calabria (Southern Italy) prospective pharmacovigilance study. Pharmaceutics. 2022;14.","DOI":"10.3390\/pharmaceutics14112449"},{"key":"774_CR16","doi-asserted-by":"publisher","first-page":"289","DOI":"10.15386\/mpr-1897","volume":"94","author":"T Larussa","year":"2021","unstructured":"Larussa T, Basile A, Palleria C, Iannelli C, Vero A, Giubilei L, et al. Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series. Med Pharm Rep. 2021;94:289\u201397.","journal-title":"Med Pharm Rep"},{"key":"774_CR17","doi-asserted-by":"crossref","unstructured":"Leone GM, Mangano K, Petralia MC, Nicoletti F, Fagone P, Past. Present and (Foreseeable) future of biological Anti-TNF alpha therapy. J Clin Med. 2023;12.","DOI":"10.3390\/jcm12041630"},{"key":"774_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ymeth.2005.01.001","volume":"36","author":"WY Hwang","year":"2005","unstructured":"Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36:3\u201310.","journal-title":"Methods"},{"key":"774_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11894-020-0745-y","volume":"22","author":"S Chang","year":"2020","unstructured":"Chang S, Hudesman D. First-Line biologics or small molecules in inflammatory bowel disease: a practical guide for the clinician. Curr Gastroenterol Rep. 2020;22:7.","journal-title":"Curr Gastroenterol Rep"},{"key":"774_CR20","doi-asserted-by":"publisher","first-page":"175628482110066","DOI":"10.1177\/17562848211006669","volume":"14","author":"G Privitera","year":"2021","unstructured":"Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, et al. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Th Adv Gastroenterol. 2021;14:17562848211006669.","journal-title":"Th Adv Gastroenterol"},{"key":"774_CR21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","volume":"18","author":"C Kapizioni","year":"2024","unstructured":"Kapizioni C, Desoki R, Lam D, Balendran K, Al-Sulais E, Subramanian S, et al. Biologic therapy for inflammatory bowel disease: Real-World comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD bioresource. J Crohns Colitis. 2024;18:790\u2013800.","journal-title":"J Crohns Colitis"},{"key":"774_CR22","doi-asserted-by":"publisher","first-page":"114","DOI":"10.5217\/ir.2021.00037","volume":"20","author":"B Barberio","year":"2022","unstructured":"Barberio B, Savarino EV, Card T, Canova C, Baldisser F, Gubbiotti A, et al. Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation. Intest Res. 2022;20:114\u201323.","journal-title":"Intest Res"},{"key":"774_CR23","doi-asserted-by":"publisher","first-page":"1169327","DOI":"10.3389\/fphar.2023.1169327","volume":"14","author":"M Li","year":"2023","unstructured":"Li M, You R, Su Y, Zhou H, Gong S. Characteristic analysis of adverse reactions of five anti-TNFa agents: a descriptive analysis from WHO-VigiAccess. Front Pharmacol. 2023;14:1169327.","journal-title":"Front Pharmacol"},{"key":"774_CR24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/apt.15097","volume":"49","author":"UN Shivaji","year":"2019","unstructured":"Shivaji UN, Sharratt CL, Thomas T, Smith SCL, Iacucci M, Moran GW, et al. Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2019;49:664\u201380.","journal-title":"Aliment Pharmacol Ther"},{"key":"774_CR25","first-page":"251","volume":"19","author":"V Solitano","year":"2023","unstructured":"Solitano V, Ma C, Hanzel J, Panaccione R, Feagan BG, Jairath V. Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2023;19:251\u201363.","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"774_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/nrd.2017.267","volume":"17","author":"DM Schwartz","year":"2017","unstructured":"Schwartz DM, Kanno Y, Villarino A, Ward M, Gadina M, O\u2019Shea JJ. JAK Inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;17:78.","journal-title":"Nat Rev Drug Discov"},{"key":"774_CR27","doi-asserted-by":"crossref","unstructured":"Velikova T, Sekulovski M, Peshevska-Sekulovska M. Immunogenicity and loss of effectiveness of biologic therapy for inflammatory bowel disease patients due to Anti-Drug antibody development. Antibodies (Basel). 2024;13.","DOI":"10.3390\/antib13010016"},{"key":"774_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.crohns.2008.05.011","volume":"2","author":"G Van Assche","year":"2008","unstructured":"Van Assche G, Vermeire S, Rutgeerts P. Management of loss of response to anti-TNF drugs: change the dose or change the drug? J Crohns Colitis. 2008;2:348\u201351.","journal-title":"J Crohns Colitis"},{"key":"774_CR29","doi-asserted-by":"crossref","unstructured":"Gisbert JP, Chaparro M. Primary failure to an Anti-TNF agent in inflammatory bowel disease: switch (to a second Anti-TNF agent) or swap (for another mechanism of Action)? J Clin Med. 2021;10.","DOI":"10.3390\/jcm10225318"},{"key":"774_CR30","first-page":"93","volume":"382","author":"BE Sands","year":"2020","unstructured":"Sands BE, Schreiber S, Lirio RA. Vedolizumab versus adalimumab for Moderate-to-Severe ulcerative colitis. Reply. N Engl J Med. 2020;382:93\u20134.","journal-title":"N Engl J Med"},{"key":"774_CR31","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.3748\/wjg.v24.i17.1868","volume":"24","author":"SC Park","year":"2018","unstructured":"Park SC, Jeen YT. Anti-integrin therapy for inflammatory bowel disease. World J Gastroenterol. 2018;24:1868\u201380.","journal-title":"World J Gastroenterol"},{"key":"774_CR32","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1007\/s10620-023-08014-z","volume":"68","author":"SK Vuyyuru","year":"2023","unstructured":"Vuyyuru SK, Solitano V, Hogan M, MacDonald JK, Zayadi A, Parker CE, et al. Efficacy and safety of IL-12\/23 and IL-23 inhibitors for crohn\u2019s disease: systematic review and Meta-Analysis. Dig Dis Sci. 2023;68:3702\u201313.","journal-title":"Dig Dis Sci"},{"key":"774_CR33","doi-asserted-by":"crossref","unstructured":"Liu E, Aslam N, Nigam G, Limdi JK. Tofacitinib and newer JAK inhibitors in inflammatory bowel disease-where we are and where we are going. Drugs Context. 2022;11.","DOI":"10.7573\/dic.2021-11-4"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00774-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00774-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00774-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:07:27Z","timestamp":1758078447000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00774-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["774"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00774-x","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human experimentation was performed. The local Ethics Committees of the Calabria Region approved the study protocol (Protocol No. 278\/2015 of 5th November 2016 and Protocol number 387 of 19th November 2020), and all studies were performed in accordance with the 1964 Declaration of Helsinki and its amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients at the time of enrolment. All procedures were executed in accordance with the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}